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Abstract 
In mammals, adipose tissue stores energy in the form of fat. The ability to regulate fat 
storage is essential for the growth, development and reproduction of most animals, thus 
any abnormalities caused by excess fat accumulation can result in pathological conditions 
which are linked to several interrelated diseases, such as cardiovascular diseases, dia-
betes, and obesity. In recent years significant effort has been applied to understand basic 
mechanism of fat accumulation in mammalian system. Work in mouse has shown that 
the family of Krüppel-like factors (KLFs), a conserved and important class of transcrip-
tion factors, regulates adipocyte differentiation in mammals. However, how fat storage is 
coordinated in response to positive and negative feedback signals is still poorly under-
stood. To address mechanisms underlying fat storage we have studied two Caenorhabdi-
tis elegans KLFs and demonstrate that both worm klfs are key regulators of fat metabo-
lism in C. elegans. These results provide the first in vivo evidence supporting essential 
regulatory roles for KLFs in fat metabolism in C. elegans and shed light on the human 
counterpart in disease-gene association. This finding allows us to pursue a more com-
prehensive approach to understand fat biology and provides an opportunity to learn 
about the cascade of events that regulate KLF activation, repression and interaction with 
other factors in exerting its biological function at an organismal level. In this review, we 
provide an overview of the most current information on the key regulatory components 
in fat biology, synthesize the diverse literature, pose new questions, and propose a new 
model organism for understanding fat biology using KLFs as the central theme.  
Key words: C. elegans, Ce-KLF-1, Ce-KLF-3, fat storage, Krüppel-like factors, KLF, Obesity, PPAR, 
C/EBP, SREBP proteins, Transcription factor 
Introduction 
Urbanization, sedentary life-styles, and an over 
abundance of high caloric foods in human popula-
tions have collectively created conditions in which the 
primordial metabolic pathways that evolved to ex-
tract optimal energy from the environment have be-
gun to function out of control [1]. Energy reserve is a 
basic property universal to all animals, from the sim-
plest of organisms, such as C. elegans, to the highly 
complex, such as humans, allowing organisms in their 
readiness to continue life in fasting and starvation. In Int. J. Biol. Sci. 2009, 5 
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mammals, excess fat is stored in adipose tissue and, 
when needed, is able to provide energy. As a complex, 
multi-factorial trait driven by natural selection based 
upon food availability, fat storage is highly regulated 
and dynamically balanced with energy consumption 
in physiological settings; its perturbation in either 
excess (obese) or deficiency (lipodystrophy) has dev-
astating pathologic consequences in the homeostasis 
and fitness of an organism. The abnormalities caused 
by excess fat accumulation can result in pathological 
conditions which are linked to several interrelated 
diseases, such as cardiovascular disease and obesity. 
This set of conditions, known as metabolic syndrome, 
is a global pandemic of enormous medical, economic, 
and social concern affecting a significant portion of 
the world’s population. Human obesity reflects an 
imbalance between energy expenditure and caloric 
intake resulting from an increase in either the number 
or the size of fat cells, or both, and is induced by the 
enlargement of adipocytes as well as the generation of 
new adipocytes from precursor cells [2]. The differen-
tiation of adipocytes consists of two distinctive steps, 
i.e., determination (fibroblasts to preadipocytes) and 
commitment (preadipocytes to adipocytes) [2]. Al-
though it is clear that genetics, physiology and envi-
ronmental components play a major role in the onset 
of obesity, little is known about how or to what extent 
each of these factors contributes to it. In addition, 
there are several other key factors, such as dietary 
habits and sedentary lifestyles, which are also re-
sponsible for excess fat accumulation in the body. 
The obese state preconditions insulin resistance 
and negatively impacts pancreatic β-cell function [3], 
two hallmarks of type 2 diabetes, a serious metabolic 
disease and health concern for worldwide popula-
tions. Obesity is further a risk factor for the develop-
ment of cardiovascular disease [4]. As adipose tissue 
stores fat the amount of adipose tissue which can be 
altered under the influence of various physiological 
conditions in an animal may be a determinant of 
energy homeostasis. In recent years, many labs have 
endeavored to understand the mechanisms that gov-
ern adipose tissue differentiation and function. 
Investigations into preadipocyte and fibroblast 
cultured cell lines have produced an abundance of 
data concerning the transcriptional cascade governing 
adipogenesis. These observations have been tested in 
transgenic and knockout mouse. As a result, a com-
plex network of transcription factors has emerged 
which includes several activators, co-activators, and 
repressors which coordinate the expression of hun-
dreds of proteins that take part in the development of 
mature fat cells under the influence of important sig-
naling pathways [5]. Three classes of transcription 
factors have been identified that directly influence fat 
cell development. These include members of PPARγ 
(Peroxisome proliferator-activated receptors), 
C/EBPα, (CCAAT/enhancer-binding proteins) and 
the basic-helix-loop-helix protein ADD1/SREBP 
(Sterol regulatory element binding proteins) families 
that are essential factors in mammalian adipogenesis 
[6, 7]. In recent years, several members of the mam-
malian Krüppel-like factor, KLF, family have been 
identified to be key players in the transcription net-
work controlling preadipocyte formation, adipogene-
sis, lipogenesis, and obesity. 
Thus far 17 members of the KLF family have 
been identified and characterized across mammalian 
systems [8, 9, 10], out of which 7 members of KLF 
family have definite role in adipogenesis. The ques-
tion of what the specific regulatory role of this family 
of genes in overall adipogenesis is, however, remains 
unclear. Insight about how KLFs influence the de-
velopment and regulation of fat storage came from 
studies which used established murine cell lines 
(3T3-L1, 3T3-F442A) and knockout mice. However, in 
vivo and in vitro mouse models provide only partial 
information [11], and the main limitation at present 
being the existence of instances in which predictions 
concerning adipose function do not translate well 
from mouse to human [4]. A genetically tractable 
model could bolster the speed of research on fat me-
tabolism which can detect new genes and pathways 
with significant roles in fat metabolism.  
One of the most challenging tasks in this line of 
research is to identify the genetic machinery of fat 
storage. Many years of development in C. elegans re-
search shows that this microscopic organism can be 
an excellent eukaryotic genetic model which may 
enable us to answer many questions concerning fat 
storage which yet remain unresolved. In the search for 
possible treatments for obesity, the C. elegans model 
should be investigated in order to explore the genetic 
component of fat storage. The free-living roundworm, 
C. elegans (commonly referred to as the worm), has 
become an increasingly useful experimental model in 
the study of genetic manipulations and overall animal 
physiology. Although a direct comparison between 
human disease pathology and C. elegans-mutant 
phenotypes is difficult, C. elegans assays mimic certain 
pathologies thereby assisting in our understanding of 
the molecular mechanisms that underlie human 
metabolic disorders. We provide a brief overview of 
what is currently known of the key components in fat 
biology, synthesize the diverse literature, suggest 
novel avenues of research, and propose a new model 
organism, for use in the study of fat storage. Over all 
we expect to exploit the unique features of C. elegans Int. J. Biol. Sci. 2009, 5 
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to provide a detailed mechanistic description of fat 
accumulation, including the identification of addi-
tional and as of yet uncharacterized components of 
the C. elegans fat storage pathway. Understanding this 
pathway may plausibly lead to the development of 
new strategies in the treatment of obesity. For exam-
ple, drugs that block or facilitate the efforts of key 
proteins involved in fat accumulation can potentially 
be developed. We present a synopsis of some of the 
important regulatory factors involved in adipogenesis 
and lipogenesis (Table 1). This review focuses on the 
main regulators of fat metabolism with an emphasis 
on the Krüppel-like factors (KLFs) which govern 
many distinct developmental and physiological 
processes and are thought to function via their en-
gagement with different coactivators and repressors. 
Transcriptional control of adipogenesis 
In order to better understand the mechanism 
underlying adipogenesis the differentiation of 
adipocytes is used as a model system for the study of 
terminal cell differentiation. This is partly due to the 
existence of well characterized cell lines such as the 
3T3-L1 preadipocyte that can be differentiated in vitro. 
The proliferation and differentiation of preadipocytes 
is characterized by apparent changes in the pattern of 
gene expression that are achieved by the orderly in-
duction of transcription  factors. When exposed to 
correct hormonal stimuli, 3T3-L1 fibroblasts become 
fat-loaded adipocytes in approximately 7 days [12, 13, 
14]. This transformation is accompanied by the 
expression of a number of adipocyte-specific factors 
as well as cell-cycle regulators that cooperatively fa-
cilitate the expression of the major transcription fac-
tors PPARγ and C/EBPα. The designated cells un-
dergo a terminal differentiation that is marked by 
both the production of lipid droplets and the ap-
pearance of the many metabolic factors unique to a 
developed fat cell. The current model for adipocyte 
differentiation suggests that during the entire differ-
entiation process there are several essential molecular 
interactions that occur among members of C/EBP, the 
PPAR families and the basic-helix-loop-helix protein 
ADD1/SREBP1c [6, 7]. C/EBPβ and C/EBPδ induce 
PPARγ, which in turn initiates the adipogenic pro-
gram that is required to promote fat cell differentia-
tion [15]. C/EBPα induces PPARγ, and continues to 
maintain PPARγ levels whilst conferring insulin sen-
sitivity to adipocytes [16].  
PPARs and C/EBPs: the master minds of 
adipogenesis  
Both PPARs and C/EBP regulate fat, glucose, 
and cholesterol homeostasis. Members of the PPARs 
family, such as PPARγ, PPARα, and PPARδ, are 
ligand-activated transcription factors belonging to the 
nuclear hormone receptor (NHR) superfamily. The 
C/EBP family, whose members include C/EBPα, 
C/EBPβ, and C/EBPδ, belong to the basic leucine 
zipper class of transcription factors. PPARγ and 
PPARα are expressed predominantly in adipose and 
liver tissue, respectively, while PPARδ is expressed in 
a variety of tissues, including adipose, brain, and skin 
tissue [17]. Within the C/EBP family, C/EBPα, 
C/EBPβ, and C/EBPδ are expressed primarily in 
adipose tissue and are associated with the main-
tainance of terminally differentiated adipocytes [18, 
19].  
The transcriptional cascade leading to adipo-
genesis involves hormonal stimulation followed by 
the rapid expression of C/EBPβ and C/EBPδ [9]. 
Within 48 hrs, the expression levels of these proteins 
peak and begin to decline, an occurrence which coin-
cides with a rise in C/EBPα and PPARγ levels. PPARγ 
and C/EBPα induce each other’s expression in a 
positive feedback loop, thereby maintaining the dif-
ferentiated cell state [20]. Studies using 
loss-of-function mutants have shown that cells lack-
ing PPARγ in vivo and in vitro express reduced levels 
of C/EBPα and are unable to undergo adipogenesis 
[11]. Conversely, cells without C/EBPα are capable of 
adipocyte differentiation but are insulin resistant, 
even in the presence of PPARγ [21]. These reports 
suggest that C/EBPα and PPARγ traverse a code-
pendent path, and that C/EBPα requires PPARγ for 
normal cell differentiation [20]. Several studies using 
cell transfection assay as well as mouse mutants im-
plicate PPARγ as the central regulator in adipocyte 
differentiation. Ectopic expression of PPARγ pro-
motes the differentiation of preadipocytes into adi-
pocytes [22]. In vivo mouse experiments show that 
cells lacking in PPARγ do not participate in the for-
mation of fat tissue [11]. In vitro, PPARγ-null cells in 
both stem cells and fibroblasts are unable to undergo 
adipogenesis [11, 20, 23], and the expression of PPARγ 
is able to restore adipogenesis in these cells. These 
experiments demonstrate the critical importance of 
PPARγ in adipogenesis.   
The two N-terminal variants of PPARγ are evi-
dently formed by their use of an alternative promoter 
and an alternative first exon. Also, PPARγ2 possesses 
an additional 30 amino acids at its extreme N termi-
nus and its expression is more adipose-specific [24]. In 
mammals, naturally occurring mutations in PPARγ 
are associated with severe lipodystrophy [25] and 
efforts to identify the site at which ligand binding to 
PPARγ occur have been unsuccessful in pharmaceu-
tical development. There exist varieties of Int. J. Biol. Sci. 2009, 5 
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fatty-acid-derived molecules that have been shown to 
bond to PPARγ, but their binding affinity is too low 
for them to be true ligands. However, there also exists 
evidence which shows that the binding and activation 
of PPARγ by a high affinity endogenous ligand is not 
necessary for adipogenesis [26]. As an NHR, PPARγ 
contains a α-helix 3 ligand-binding domain at its C 
terminus. As a result of a screening of colon cancer 
cells Sarraf and colleague (1999) identified a mutation 
in the α-helix 3 ligand-binding domain that caused a 
glutamine-to-proline shift at residue 286 (Q286P) [27]. 
They found that without agonist treatment, wild-type 
PPARγ and mutant PPARγ Q286P were both adipo-
genic. This would suggest that the activation of these 
proteins is not dependent on PPARγ agonist ligands 
under physiological conditions [26]. There has been 
also report that PPARs play significant roles in both 
type-2-diabetes and atherosclerosis [28]. It is known 
that antidiabetic drugs, thiazolidinediones, act as 
PPARγ-agonists that block vascular smooth muscle 
cell growth and migration, thus potentially reducing 
atherosclerosis [29]. Whereas PPARδ has been linked 
to lipid accumulation in human macrophages that 
leads to atherosclerosis, arthritis, and neourodegen-
eration [30], the PPARα acts as a heterodimer with the 
retinoid X receptor [31], inducing the transcription of 
target genes involved in fat metabolism. Unsuitable 
signaling by retinoid X complexes contributes to a 
host of severe pathologies which includes diabetes, 
heart disease, and obesity. PPARα is an essential 
regulator in fatty acid metabolism whose activation 
results in reduced serum levels of triacylglycerides, 
free fatty acids, and cholesterol. Consequently, syn-
thetic PPARα ligands are known to be efficient 
lipid-lowering drugs used in the treatment of diabetes 
[32]. The discovery of PPARs and C/EBPs has paved 
the way for new avenues in lipid research by ad-
vancing our knowledge about adipogenesis at a mo-
lecular-level.  
Sterol regulatory element binding proteins 
(SREBPs): the housekeepers of lipid homeo-
stasis 
Aside from core adipogenic factors, PPARs and 
C/EBP, regulatory factor that impact adipogenesis 
has been identified. The sterol regulatory element 
binding proteins (SREBPs) regulate lipid homeostasis 
by controlling the expression of a range of enzymes 
required for endogenous cholesterol, fatty acid (FA), 
triacylglycerol and phospholipid synthesis [33]. 
SREBP protein is essentially a housekeeping protein 
responsible for the regulation of the lipid composition 
of cell membranes, contributing to overall lipid ho-
meostasis. There are three SREBP isoforms, SREBP-1a, 
SREBP-1c and SREBP-2 known thus far. However, 
each SREBP isoform possesses exclusive regulation 
and activation properties that facilitate the 
co-ordinate regulation of lipid metabolism [33] and is 
found as a membrane-bound precursor in the endo-
plasmic reticulum. Membrane lipids (sterols and 
polyunsaturated fatty acids) control SREBP activities 
through feedback mechanisms. While SREBP-1a and 
SREBP-1c selectively induce the expression of genes 
involved in fatty acid biosynthesis [34], SREBP-1c is 
additionally involved in adipose differentiation [35]. 
Kim and colleagues (1998a) have shown that the ex-
pression of SREBP-1c increases in response to insulin, 
in 3T3-L1 adipocytes and in turn putatively controls 
the regulation of adipogenesis [36]. By analogy, the 
ectopic expression of a dominant-negative SREBP-1c 
prevents preadipocyte differentiation [37] and facili-
tates PPARγ activity through the production of an 
endogenous ligand [38]. Interestingly, SREBP-2 acts as 
a putative gene inducer functioning in the cholesterol 
biosynthesis pathway [33]. 
The most toxic of the congeners, 
2,3,7,8-Tetrachlorodibenzo-p-dioxin, up-regulates 
SREBP activity in the liver while down-regulating its 
activity in adipose tissue [39]. Collectively these 
metabolic changes may be linked to the onset of 
wasting syndrome. This syndrome results in a disor-
dered distribution of lipids resulting in diabetes-like 
symptoms and a fatty liver pathology [40]. The im-
portance of tight regulatory activities of SREBPs in the 
fat storage pathway is evident, we still know little 
about the effects of SREBPs on overall animal physi-
ology. Because of the lack of a suitable model organ-
ism, the majority of physiological insights are gener-
ated from in vitro studies. Six years ago, McKay and 
colleagues [41] investigated C. elegans as a model 
organism for use in the study of the molecular 
mechanisms that control adipocyte formation. They 
took advantage of the complete genome sequence 
available on the C. elegans data base 
(www.wormbase.org). The existence of C. elegans 
homologs of mammalian SREBP and C/EBP led these 
researchers to examine whether C. elegans SREBP and 
C/EBP have roles in fat storage. The Ce-SREBP 
(Y47D3B.7;  lpd-1) is exclusively expressed in the 
intestines while Ce-C/EBP (C48E7.3; lpd-2) is weakly 
yet extensively expressed in the nervous system 
(www.wormbase.org). Disruption of either C/EBP or 
SREBP by RNAi results in pale, skinny, 
lipid-depleted, and developmentally-arrested worms 
[41]. Although both SREBP and C/EBP RNAi worms 
did eat and defecate normally, they did not possess fat 
granules. This data suggests that the SREBP and 
C/EBP required for mammalian adipocyte Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
626
differentiation are also essential for the fat storage in 
the worms. Interestingly, SREBP and C/EBP regulate 
the expression of the same lipogenic enzymes in both 
worms and mammals [41]. The role of SREBPs in 
adipogenesis and the connection between SREBPs 
and metabolic disorders remains to be a division of fat 
biology in which important discoveries continue to be 
made. The data obtained concerning worm SREBP 
and C/EBP in relation to their function in fat accu-
mulation has the potential to serve as a model for 
mammalian fat storage. The C. elegans possesses a 
clear homolog of C/EBP, of the 284 NHRs encoded by 
the  C. elegans genome, however, none exhibit se-
quence identity with PPARs. C. elegans possesses 
several genes which display similarity to PPARγ, 
making the identification and investigation of a po-
tential PPARγ homolog difficult [42].  
Other adipogenic factors 
In addition to PPARγ, C/EBPs, and SREBPs, a 
number of other factors have been recently found to 
be involved in the regulation of adipogenesis, for 
example FoxO1. It has been shown that the overex-
pression of a constitutively active fork-head contain-
ing transcription factor FoxO1 in 3T3-L1 preadipo-
cytes blocks adipogenesis by increasing cyclin-kinase 
inhibitor p21 expression and blocking clonal expan-
sion [43]. Further study has shown that FoxA2 inhibits 
adipogenesis by inducing the expression of preadi-
pocyte factor-1 (DLK1/Pref-1) [44]. Still, the expres-
sion of the third member of the family, FoxC2, is con-
fined to adipose tissue in mice, supporting only the 
differentiation of brown adipocytes, not white adi-
pocytes [45]. Another adipogenic factor, the zinc fin-
ger-containing transcription factor Krox20 (early 
growth response gene 2, or Egr2) has reported to act 
early in the adipogenic program of 3T3-L1 cells and 
seems to contribute to the induction of C/EBPβ ex-
pression. This induction may occur by activating an-
other intermediary transcription factor, such as a 
homeobox family protein. GATA factor family of 
transcription factor has been known for its importance 
in many gene regulations in diverse physiological 
processes. GATA2 suppresses adipogenesis [46]. 
During cell differentiation, the expression of GATA2 
is down-regulated, thus exerting its negative effects 
on adipogenesis by suppressing pparg2 promoter ac-
tivity [47]. After extensive search of body of literatures 
indicates that although many transcription factors 
have essential regulatory roles in adipose cell differ-
entiation, it is likely that most of these factors interact 
with PPARγ and the C/EBPs, these two proteins re-
main the master regulators of adipogenesis. 
Krüppel-like factors (KLFs): the new kids on 
the block 
The Krüppel-like factors are an important family 
of Cys2/His2 zinc-finger DNA-binding proteins ho-
mologous to the Drosophila melanogaster segmentation 
gene product, Krüppel. The C terminus zinc fingers 
bind to the CACCC/GC/GT-box found in the regu-
latory regions of genes, controlling various biological 
processes [48]. The N terminus is highly variable and 
involved in gene activation, gene repression, or both, 
as well as in protein-protein interactions [48]. KLFs 
are known to participate in cell proliferation, differ-
entiation, hematopoiesis [49, 50, 51], and cell cycle 
progression [52]. All KLFs bind to similar DNA se-
quences which consist of CACCC or related GC-rich 
elements in the promoter and enhancer regions, an 
occurrence which leads to a remarkable overlap in the 
target genes that KLFs regulate. Despite these com-
mon features, the majority of KLFs have unique tis-
sue-specific roles, a fact which explains why the exact 
function of KLFs in vivo as well as their target speci-
ficity is poorly understood. Eight members of mam-
malian KLFs: KLF2, KLF3, KLF4, KLF5, KLF6, KLF7, 
KLF-11 and KLF15 have been identified as key com-
ponents of transcription network responsible for con-
trolling adipocyte differentiation, adipogenesis, and 
obesity [53-57]. Interestingly, the functional CACCC 
binding sites are found in the control region of key 
adipogenic factors, such as C/ebpα and PPARγ. We 
will focus on these KLFs, the variability in their ex-
pression patterns during adipocyte differentiation, 
and their effects on adipogenesis and gene expression 
(Table-1).  
 
 
 Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
627
Table 1. Roles of key molecular components in lipid biology.  
Term or acronym  Definition  Role(s) 
CPB  p300/cAMP response element-binding protein  A transcriptional co-activator 
CREB  cAMP response element binding  A transcription factor that regulates gene expression in con-
junction with cAMP 
C/EBPα  CCAAT/enhancer-binding protein alpha  Involved in insulin resistance in cells 
C/EBPβ  CCAAT/enhancer binding protein beta  Can activate KLF5 transcription  
C/EBPδ  CCAAT/enhancer binding protein delta  Can activate KLF5 transcription 
CtBP  C-terminal binding protein  A transcriptional repressor, Repressor of proapoptotic genes 
DAF  Insulin receptor-like   Insulin-like receptor in worm 
FAT  Delta-9 fatty acid desaturation enzyme genes  Genes involved in the synthesis of ∆9 desaturase 
FOXO  A subset of the Forkhead box “FOX” family of tran-
scription factors 
Transcription factors involved in a wide array or processes; 
involved in insulin signaling 
GLUT4  Insulin-regulated glucose transporter 4  Involved in insulin-regulated glucose disposal 
HDAC3  Histone deacetylase 3  A transcriptional repressor  
HIT-T15  Cell line derived from human pancreatic islet beta cells Used as a model system for fat biology 
    
KLF  Krüppel-like factor  Transcription factors involved in a wide array of cellular proc-
esses; regulation of adipogensis 
KLF2  Krüppel-like factor 2.   Negative regulator of adipocyte differentiation and adipo-
genesis 
KLF3  Krüppel-like factor 3  Negative regulator of adipogenesis 
KLF4  Krüppel-like factor 4  Positive regulation of adipogenesis; can down regulate 
C/EBPβ levels 
KLF5  Krüppel-like factor 5.  
 
Involved in the induction of PPARγ and positive regulation of 
adipogenesis 
KLF6  Krüppel-like factor 6  Positive regulator of adipogenesis through PPARγ 
KLF7  Krüppel-like factor 7  Negative regulator of adipogenesis through insulin regulation 
KLF11 
 
Krüppel-like factor 11 
 
glucose-induced regulator of the insulin gene 
 
KLF15  Krüppel-like factor 15 
 
Preadipocyte differentiation to adipocytes, positive regulator of 
adipogenesis 
NHR  Nuclear hormone receptor   Regulates fat usage 
NHR-49  Nuclear hormone receptor 49  Control consumption of fat and maintains a normal balance of 
fatty acids 
NHR-80  Nuclear hormone receptor 80  Isoform of NHR-49 with similar functions 
HLH Helix-loop-helix  Transcription  factor  protein that regulates stearoyl-CoA de-
saturases 
Krox20  Krox20 protein  Protein that promotes expression of C/EBPβ and, with 
C/EBPβ, facilitates terminal adipogenesis 
    
N-CoR  Nuclear receptor corepressor  A transcriptional co-regulatory protein 
    
PPARα  Proliferator-activator receptor alpha  Involved with retinoid x receptor proteins to regulate genes 
involved in fat metabolism 
PPARγ Proliferator-activator  receptor  gamma  Master regulator of adipogenesis; Fatty acid metabolism: lipo-
genesis and fat storage 
    
PPARδ  Proliferator-activator receptor delta  Fatty acid metabolism: catabolism 
Retinoid Xreceptor  Retinoid X receptor   A type of nuclear receptor activated by 9-cis retinoic acid and 
involved in regulating genes involved in fat metabolism as a 
heterodimer with PPARα 
    
SCD  Stearoyl-CoA desaturases  An important enzyme in fat metabolism and insulin signaling 
SCD1 Stearoyl-CoA  desaturases 1  Involved in inducing adipogenesis 
SP-1  Specificity protein 1  Transcription factor involved in early development 
SREBP  Sterol regulatory element binding protein  Transcription factor protein that regulates stearoyl-CoA de-
saturases 
SREBP-1a  Sterol regulatory element binding protein 1a  Regulator of lipid metabolism 
SREBP-1c  Sterol regulatory element binding protein 1c  Involved in adipose differentiation and adipogenesis; facilitates 
PPARγ activity 
SREBP-2  Sterol regulatory element binding protein 2  Induces genes in the cholesterol biosynthesis pathway 
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Pro-adipogenic KLFs: 
Krüppel-like factor 15 was the first KLF to be 
found to be involved in adipogenesis. KLF15 partici-
pates in adipogenesis through its regulation of PPARγ 
expression. In addition to this, the overexpression of 
KLF15 both induces adipocyte differentiation and 
positively regulates the expression of the insu-
lin-glucose transporter-4 (GLUT4) [54]. In an experi-
ment involving microarray analysis, KLF15 was 
shown to be up-regulated when induced 3T3-L1 
preadipocytes differentiated into adipocytes; it has 
been shown that blocking the expression of KLF15 by 
use of either a dominant negative mutant or through 
RNAi reduces the expression of PPARγ and prevents 
adipogenesis [55]. Notably, the dominant negative 
mutant of KLF15 does not affect the expression of 
C/EBPβ [34]. In NIH 3T3 cells, C/EBPβ and C/EBPδ 
activate KLF15  and acting together, KLF15 and 
C/EBPα increase the expression of PPARγ following a 
decrease in C/EBPβ and C/EBPδ transcript levels 
[55]. PPARγ is further able to elevate C/EBPα levels, 
indicating that a positive feedback mechanism exists 
between the two factors [16]. An additional related 
factor, KLF4, is an essential early regulator of adipo-
genesis. KLF4, also known as GKLF/ZIF, is highly 
expressed in differentiated, post-mitotic cells of the 
skin and the gastrointestinal tract and possesses a 
variety of roles as a differentiation-proliferation 
switch and regulator of the cell cycle [58, 59, 60]. 
When KLF4 activity was eliminated the KLF4 
knockout mice died approximately 12 hours after 
birth due to defects in skin development coupled with 
a failure to form a normal basement membrane [61]. 
The fat layer of the skin of those mice was disrupted, 
resulting in a malfunctioning of the skin barrier and 
by a rapid loss of body fluids. These significant al-
teration in mouse suggest that KLF4 has a critical 
regulatory role in the development of adipose tissue. 
Studies in 3T3-L1 cell lines indicated that KLF4 is ex-
pressed in these cells within 30 minutes of exposure to 
a standard adipogenic cocktail. However, elimination 
of KLF4 activity in 3T3-L1 cells inhibits adipogenesis 
and down regulates C/EBPβ levels [56], suggesting 
that KLF4 is an upstream transcriptional regulator of 
C/EBPβ in the network controlling adipogenesis. 
Notable is the observation that KLF4 binds directly to 
the C/EBPβ promoter and, in concert with Krox2 [62], 
markedly transactivates C/EBPβ expression [56]. 
Conversely, the knockdown of C/EBPβ increases 
KLF4 expression while an overexpression of C/EBPβ 
decreases KLF4 expression, indicating that C/EBPβ 
reduces klf4 gene expression through negative feed-
back [56].   
Another important member of KLF family, KLF5 
also known as basic transcription element-binding 
(BTEB)2, or intestinal-enriched Krüppel-like factor, is 
a key element involved in the pathogenesis of car-
diovascular disease. KLF5 regulates the proliferation 
of various cell types, including fibroblasts, smooth 
muscle cells, white adipose tissue and intestinal 
epithelial cells. Recently, KLF5 has been noted to be a 
key player in the transcription factor network which 
controls adipocyte differentiation. KLF5 is expressed 
early in adipocyte differentiation at the point at which 
C/EBPβ/δ binds directly to the KLF5 promoter [63]. 
KLF5 then acts in concert with early factors, C/EBPβ 
and C/EBPδ, in facilitating the expression of the late 
factor, PPARγ2, mediating the early and late stages of 
adipogenesis in neonatal heterozygous KLF5 knock-
out mice [63]. There is evidence to support that the 
SUMOylation of KLF5 acts as a molecular switch in 
response to PPARδ and the adipogenic signals that 
can activate or repress the genes involved in lipid 
synthesis [64]. A PPARδ isoform is expressed in 
skeletal muscle, blocking its expression decreases the 
muscle’s oxidative capabilities, leading to obesity and 
glucose intolerance [65]. Conversely, an overexpres-
sion of PPARδ protects mice from contracting 
diet-induced obesity [66]. The reversible nature of 
SUMOlyation makes it a major regulatory modifica-
tion moiety which leads to transcription inhibition 
[67]. Under basal conditions in response to cellular 
and environmental stress, SUMoylated KLF5’s bind-
ing to the corepressor N-CoR (nuclear receptor 
corepressor) and SMRT (silencing mediator of reti-
noid and thyroid receptor) is increased, while its af-
finity for CREB binding proteins and PPARδ is de-
creased and fatty acid metabolism is suppressed [64]. 
KLF5 further acts as a key regulator, controlling the 
expression of FASN (fatty acid synthase) through an 
interaction with SREBP-1. KLF5 binds to SREBP-1 
and additionally enhances the SREBP-1-mediated 
increase in FASN promoter activity [68].   
The Krüppel-like factor 6, a tumor suppressor 
gene, appears to promote adipogenesis by the tran-
scriptional suppression of proto-oncogene delta-like 1 
(Dlk1). The DLK1 is a transmembrane protein that 
inhibits adipocyte differentiation through its interac-
tion with HDAC3 [69]. A cell culture study suggests 
that HDAC3 deacetylase represses PPARγ function as 
result of its interaction with hypophosphorylated 
retinoblastoma (pRb) [70]. Although pRb interacts with 
a considerable number of growth-promoting tran-
scription factors [71, 72], few studies suggest that pRb 
phosphorylation is involved in preadipocyte differ-
entiation [73, 74]. Li et al. (2005) [69] demonstrated 
that KLF6 could, independent of Rb, moderate adi-Int. J. Biol. Sci. 2009, 5 
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pocyte differentiation through the transcriptional ac-
tivation of adipocyte inducers such as PPARγ, 
C/EBPα/β, and steroyl-CoA desaturase-1 (SCD1).  
KLFs as negative regulators: 
Other KLFs (i.e., KLF2, KLF3, and KLF7) func-
tion to block adipogenesis. For instance, the KLF2 is 
amply expressed in younger preadipocytes, yet dis-
plays reduced expression in mature adipocytes. Con-
stitutive expression of KLF2 results in an inhibition of 
PPARγ expression but does not have any effect on the 
upstream regulators C/EBPβ and C/EBPδ [75]. Using 
a combination of promoter mutational analysis and 
gel mobility shift assays, a binding site identified 
within the PPARγ2 promoter has been found to be 
responsible for the inhibitory effects of KLF2 [75]. Wu 
et al. (2005) [76] generated tetracycline-responsive 
lines of 3T3-L1 which expressed physiological levels 
of KLF2 and were thus able to show that KLF2 pre-
vented preadipocyte differentiation by partially re-
storing preadipocyte factor-1 (Pref-1). As evidenced 
by the formation of lipid globules, embryonic cells 
derived from KLF2-/- lines can differentiate into adi-
pocytes, implying that the presence of KLF2 is not 
important during the formation of preadipocytes, but 
rather during later development, when it inhibits 
preadipocyte maturation into adipocytes. In 3T3-L1 
cell line, the forced expression of mammalian KLF-3 
blocks adipocyte differentiation as result of a direct 
association with the C/ebpα promoter, whilst a de-
crease in KLF-3 levels prevents differentiation [77]. 
The  klf-3 deficient mice created by disrupting klf-3 
gene by homologous recombination were smaller 
than wild-type showed a significant reduction in 
white adipose tissue [77]. Further analysis of the fat 
pads in knock out mice indicated that pads contained 
fewer and smaller cells. Turner and Crossley (1998) 
observed that KLF3 inhibits transcription by recruit-
ing to its N terminal repression domain the corepres-
sor C-terminal binding protein (CtBP) [78].  
The Krüppel-like factor 7, KLF7, has also been 
implicated as a negative regulator of adipogenesis. 
Significantly, KLF7 has been linked to the pathogene-
sis of type 2 diabetes. Kawamura et al (2005) over 
expressed KLF7 in insulin secreting cell line (HIT-T15 
cells) and showed that the modest increase in KLF7 
expression dramatically suppressed the glu-
cose-induced secretion of insulin and reduced the 
expression PPARγ and C/EBPα, thereby blocking 
adipogenesis [79]. KLF11 is known to be a pan-
creas-enriched transcription factor. Both in vitro and 
in vivo studies have shown KLF11 to be a negative 
regulator of exocrine cell growth. Neve and colleague 
(2005)[80], in performing detailed functional and ge-
netic analyses of KLF-11, found that KLF11 is a glu-
cose-induced regulator of the insulin gene and that 
functional KLF11 gene variants possess a significant 
association with diabetes. Although KLF-11 has been 
proposed to be a glucose-induced regulator of the 
insulin gene [80], this protein may also been involved 
in adipogenesis and metabolic control [81]. 
A greater understanding of the mechanisms 
governing adipogenesis will emerge with use of a 
model organism in which changes in cellular devel-
opment are associated with observable genetic modi-
fications. Several laboratories have demonstrated that 
vertebrate KLFs, as well as other regulators, are key 
players in fat storage pathways [63, 55, 76]. As the 
majority of these reports have come through bio-
chemical and tissue culture studies, a good genetic 
model organism is needed for a thorough examina-
tion of the fat storage process in vivo during the de-
velopment of an organism. To better understand how 
KLFs regulate fat storage, our laboratory uses C. ele-
gans as a model organism. Many of the regulatory 
genes involved in C. elegans fat metabolism are in-
volved in adipocyte biology [82]. This relatively sim-
ple organism provides a powerful system to study the 
genes with critical roles in human metabolic diseases. 
C. elegans fat biology 
The worm Caenorhabditis elegans has emerged as 
a powerful molecular genetic model for use in study-
ing genes which possess vital roles in human health 
and diseases. A number of studies reported thus far 
have already shown significant similarities between 
molecular components of mammalian and C. elegans 
fat pathways that extend to disease-associated genes. 
Recent studies have shown that fat regulation in C. 
elegans engages a complex network of genes with 
likely functions in food sensation, neuroendocrine 
signaling [94, 84], uptake, transport [85], and storage 
[41]. The C. elegans stores fat in intestine, an organ 
derived from the endodermal layer and composed of 
several types of gut granules which contain protein, 
carbohydrate molecules, and lipid fat granules. In 
contrast, mammalian fat is stored in a derivative of 
mesodermal tissue which contains a single cell type, 
the adipocyte. The mammalian adipoctye is dedicated 
to maintaining a homeostasis in fat metabolism, 
whereas the worm intestine is responsible for many 
diverse functions. Although they are clearly distinct, 
the common factor between C. elegans and mammal-
ian adipocytes is the genetic conservation of the 
regulation of fat granules [41]. Though C. elegans does 
not have a dedicated adipocyte, the shared worm and 
mammalian fat regulatory pathways link to the de-
velopmental programs that underlie fat storage ca-Int. J. Biol. Sci. 2009, 5 
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pacity. Several of the recently discovered C. elegans fat 
regulatory pathways play roles resembling those 
found in mammals. For example, there is evidence to 
support the existence of neuropeptide, serotonergic, 
and insulin signaling pathways that regulate fat 
storage in both nematodes and mammals [86, 87, 88].  
It is well established that fat storage is 
profoundly influenced by differing environmental 
conditions, it is now possible to uncover the 
mechanism by which physiological pathways are able 
to adjust themselves in response to various 
environmental cues. Thus the questions concerning to 
what extent and by what mechanism, age, food, and 
habitat disturb the fat storage networks of C. elegans 
can be addressed at a molecular level. The C. elegans 
genome contains several fat regulators, an array 
which includes various transcription factors, signal 
transduction modules, nutrient transporters, and 
biochemical identities and pathways, that are ho-
mologous to a wide range of mammalian genes (C. 
elegans Sequencing Consortium 1998) [89]. Through 
the use of a genome-wide RNAi worm analysis, Ash-
rafi et al. (2003) [84] identified 305 C. elegans genes 
which, when suppressed, decreased body fat, in ad-
dition to 112 more genes whose inhibition enhanced 
fat storage. Furthermore, through an examination into 
the effects of fat-reducing gene inactivation in various 
C. elegans insulin, serotonin, tubby and nuclear sig-
naling mutants [90, 91, 92], this group found a new set 
of fat regulatory genes. Monounsaturated fatty acids 
(MUFAs) are integral components of both membrane 
phospholipids and lipid stored triglycerides, playing 
critical roles in key cellular process such as cell com-
munication and energy storage. C. elegans can synthe-
size a wide variety of fatty acids using Δ12, Δ3, Δ5, Δ6, 
three Δ9 desaturases [93], and elongases [94].   
The suppression of daf-2 in C. elegans corre-
sponds with insulin resistance and type 2 diabetes in 
humans. Several C. elegans daf-2 mutants build up fat 
deposits instead of leading to glucose metabolism, 
causing metabolic and developmental changes (i.e., 
increase in life-span) [85]. A related study using a 13C 
isotope assay to quantify the contribution of dietary 
fat to de novo synthesis found that alternative alleles of 
daf-2 do not increase fat synthesis, suggesting that 
site-specific mutations in the insulin receptor can dif-
ferentially influence longevity and metabolism [95]. 
The deletion of a C. elegans nhr-49 caused increased fat 
accumulation and decreased life span in worms [92]. 
NHR-49 serves as a key regulator in fat usage, ad-
justing the pathways that control fat consumption and 
maintaining a normal balance of fatty acids. A simi-
larity between the biological activity of nhr-49 in C. 
elegans and that of mammalian PPARs is suggestive of 
an evolutionarily conserved role for NHRs in modu-
lating fat consumption and composition [64]. These 
studies illustrate the significance of C.  elegans as a 
model organism for use in fat biology and in advanc-
ing our knowledge of whole-organism metabolism 
and physiology. We highlight recent advances in the 
role of C. elegans KLFs in fat metabolism as well as 
their links to human metabolic disorders. 
Role of KLFs in C. elegans fat storage 
The  C. elegans genome predicts three KLFs, 
which include the gene F56F11.3, referred to as klf-1 
[96], gene F53F8.1 (klf-2; a homolog of humanWT1), 
klf-3a,  and klf-3b ( mua-1a; F54H5.4 and mua-1b; 
F54H5.4b; Wormbase; http://www.wormbase.org.) 
[97]. All three C. elegans KLFs, klf-1, klf-2 and klf-3, 
share the highest identity with members of mammal-
ian KLFs in terms of their C-terminal C2H2 zinc fin-
gers, despite little homology in their N-terminal re-
gions. Since klf-1 mutant is not available, RNAi was 
used to suppress klf-1 activity in C. elegans. When 
KLF-1 functioned normally, the worms had typical fat 
deposits in their intestines, but when klf-1 activity was 
suppressed, the worms lost their ability to store ap-
propriate levels of fat and instead accumulated ab-
normally high amounts of fat in their intestines (Fig-
ure 1B). Our findings are therefore consistent with the 
observed expression profile of klf-1::gfp in C. elegans 
intestines (Figure 1A). The worm intestine, a major 
endocrine organ which engages in nutrient sensing 
and energy metabolism, is positioned close to the 
sexual organs and a major tissue engaged in nutrient 
sensing and energy metabolism [98]. In C. elegans, the 
intestine performs several diverse functions which are 
executed by many different organs in higher eu-
karyotes. The key function of C. elegans intestinal cells 
appears to be digestive as they can be observed to 
secrete digestive enzymes into the lumen of the intes-
tine and take up the processed material and nutrients. 
In hermaphrodites, yolk protein is synthesized in the 
intestine and then transported to the oocytes through 
the body cavity [99]. Significantly, the intestine serves 
as the major site for fat storage [100], for fatty acid 
metabolism, and is a storage depot with a large 
number of assorted storage granules. We also found 
that over-expression of klf-1::gfp caused severe 
egg-laying defects in C. elegans while a suppression 
resulted in increased cell death. Our results further 
imply that the inhibition of klf-1activity disrupts cell 
phagocytosis. An increase in fat accumulation in the 
absence of Ce-klf-1, its expression pattern in the intes-
tine during larval development, as well as the con-
tinued presence in adult worms suggest that C. elegans 
klf-1plays a critical role in the regulation of fat me-Int. J. Biol. Sci. 2009, 5 
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tabolism; a disturbance in this process may increase 
cell death and cause the defective phagocytosis of 
dead cells [96].  
 
 
Figure 1. (A) The expression of klf-1::gfp. Intense ex-
pression of gfp green fluorescent in the intestine of a C. 
elegans adult hermaphrodite; (B) extensive fat accumula-
tion in klf-1RNAi hermaphrodite; (C) low fat content in 
wild type adult hermaphrodite. Both wild type and RNAi 
worms were detected by Nile Red staining. Worms were 
observed and photographed using Axioskop 2 plus fluo-
rescent microscope (400X magnifications). 
 
Research is underway in our laboratory to define 
the underlying molecular mechanisms which lead to 
the increased fat accumulation, cell death, and 
phagocytosis following KLF-1 misregulation. Fat me-
tabolism is known to be a complex process requiring a 
number of molecules involved in the absorption, 
biosynthesis, assembly, transport and catabolism of 
diverse lipids. The suppression of klf-1 activity may 
result in a failure in to regulate the specific genes 
needed in one or more of these processes. The 
complex and extensive array of metabolic abnormali-
ties that result from excess fat accumulation may also 
be linked to excessive cell death. Alternatively, cell 
death in the klf-1 RNAi worms may have occurred as 
result of a failure to induce the genes required to 
prevent cell death. To elucidate whether Klf-1 
functions in a known regulatory pathway or in a yet 
unknown new pathway, a thorough analysis of the 
cellular functions of C. elegans klfs, accompanied by a 
scrutiny of their interactions with each other and 
other molecular components of fat regulatory 
pathways is needed. 
We have continued our studies on C. elegans 
KLF. Recently we have identified a critical role of 
Ce-KLF-3 in fat metabolism [97]. In order to gain in-
sight into the mechanisms by which C elegans  klfs 
regulate fat storage, we examined two mutant alleles 
of C. elegans klf-3. We performed detailed genetic and 
phenotypic analyses and have thereby shown that the 
two alleles of klf-3 mutants, klf-3(ok1975)  and 
mua-1(rh160), carry different genomic deletions, with 
each exhibiting distinctive loss-of-function pheno-
types. A partial characterization of a C. elegans mua-1 
(rh160) allele suggests a role in the mechanical integ-
rity of the skeletal muscle in the worm [101]. A dele-
tion in mua-1 (rh160) II mutants caused the animals to 
grow inadequately, the majority failed to reach 
adulthood. These mutants have defects in the cell 
matrix attachments that are critical in the transmission 
of muscle contractions to the cuticle as well as in the 
attachment of the uterus to the body wall [101]. A 
detailed molecular analysis of mua-1 ( rh160) II mu-
tants confirmed that a more extensive genetic disrup-
tion had occurred that affected two other neighboring 
genes in addition to mua-1. Although mua-1 functions 
in muscle development, a further analysis of the 
mua-1 deletion within its own coding sequence is cru-
cial in order to gain insight into the full spectrum of 
functions performed by mua-1. However, the 
klf-3(ok1975) allele, characterized by a 1658-bp dele-
tion in the klf-3 gene spanning the 3’ end of exon 2 A 
in the klf-3 coding sequence which causes a loss in klf-3 
function, subsequently resulting in severe reproduc-
tive defects in mutant worms. Klf-3 is exclusively ex-
pressed in the intestine of both larvae and adult 
worms increases the amounts of fat deposited in the 
intestine [97]. We extended this study to a mammalian 
adipocyte model. The mouse 3T3-L1 preadipocyte is a 
cellular model in which adipogenesis is studied 
through the use of defined media and hormones. We 
explored its utility in order to determine whether 
worm  klf-3  would be able to function in this het-
erologous system and manifest a conserved regula-
tory role. We tested the expression of worm klf-3 in 
this cell line via transfection with a Ce-Klf3::gfp plas-
mid and were able to determine its sub-cellular loca-
tion. Interestingly, Ce-klf-3 localizes in the nucleus of 
mouse 3T3-L1 preadipocytes, supporting the asser-
tion that it functions as a transcription factor in gene 
expression within the nucleus. In order to examine the 
role of transiently expressed Ce-klf-3 during preadi-
pocyte to adipocyte differentiation, we induced 
3T3-L1 cells with a hormone mix supplement. We 
found that an overexpression of Ce-klf-3 both signifi-
cantly blocks cell differentiation (Figure 2 D) and 
down-regulates pro-adipogenic genes PPARγ 
(Hashmi et al., unpublished) in the presence of the Int. J. Biol. Sci. 2009, 5 
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hormone mix. These occurrences resemble the char-
acteristics of overexpression of KLF2 in 3T3-L1 cells 
[76]. Mammalian KLF2 is known to be a negative 
regulator in adipocyte  differentiation. An Overex-
pression of KLF2 inhibits PPARγ expression with no 
effects  on the upstream regulators C/EBPβ and 
C/EBPδ. KLF2-/- cells do not exhibit a significant dif-
ferences in lipid accumulation when compared with 
KLF2+/+ after 12 days of differentiation, however, 2 
days following confluence (day 0 of differentiation), 
KLF2-/- cells displayed considerably more lipid de-
posits (~10-fold) in comparison to those of wild-type 
cells. At the initial stage of differentiation, i.e., day 
1−3, KLF2-/- cells still exhibit about 100% more lipid 
accumulation than do KLF2+/+ cells [76]. Taken to-
gether, this data establishes mouse 3T3-L1 preadipo-
cytes to be feasible heterologous model systems when 
endeavoring to evaluate the conserved regulatory 
functions of the worm klf-3 gene. 
 
 
Figure 2. Over-expression of worm klf-3 in mouse 3T3-L1 
preadipocyte cells. A) cell without induction; B) klf-3 
transfected cell without induction; C) cell after induction; 
D) klf-3 transfected cell after induction; E) cell transfected 
with vector (pEGFP) alone and after induction. Note that 
klf-3  significantly suppress the formation of fat droplets, 
probably acting as a negative regulator of adipogenesis. 
 
The dramatic phenotype observed in the klf-3 
(ok1975) mutant suggests that klf-3 plays a key role in 
fat regulation and that its deletion interferes with lipid 
metabolism and signal transduction associated with 
fat storage. We recently tested this hypothesis by 
performing microarray and qRT-PCR using RNA 
extracted from klf-3 mutant worms and compared this 
with RNA obtained from wild type worms. We found 
that a deletion in the klf-3 coding sequence had a 
profound effect on multiple genes involved in the 
fatty acid β-oxidation (mitochondrial β-oxidation and 
peroxisomal  β-oxidation) pathways [97](Table-2). 
Fatty acids in the form of Acyl-CoA molecules are 
broken down in mitochondria and/or peroxisomes in 
order to generate Acetyl-CoA. This process requires 
three major events to occur: i) activation and transport 
into mitochondria, ii) β-oxidation, and iii) electron 
transport chain. Fatty acids are first transported 
through the outer mitochondrial membrane by 
carnitine-palmitoyl transferase I (CPT-I) and are then 
dispatched across the inner mitochondrial membrane 
by carnitine [102]. The action of CPT-I is known to be 
the rate limiting step in fatty acid oxidation. Once 
inside the mitochondrial matrix, fatty acids undergo 
β-oxidation. During this process, two-carbon 
molecules, contained in acetyl-CoA, are repeatedly 
cleaved from the fatty acid. Acetyl-CoA is then able to 
enter the TCA cycle, which produces NADH and 
FADH. NADH and FADH are subsequently used in 
the electron transport chain to produce ATP. Fatty 
acid oxidation also occurs in peroxisomes, which 
carry out initial oxidation when fatty acid chains 
become too long (>C-22), and cannot be processed in 
mitochondria. However, the oxidation of fatty acids in 
peroxisomes is not coupled with ATP synthesis. 
Instead, high-potential electrons are transferred to 
oxygen, yielding hydrogen peroxide. The enzyme 
catalase, found exclusively in peroxisomes, converts 
the hydrogen peroxide into water and oxygen. 
Peroxisomal β-oxidation requires the action of special 
enzymes specific to peroxisomes and very long fatty 
acids. Thus the reduced expression of the genes that 
facilitate the transport and breakdown (Table-2) of 
fatty acids could plausibly cause the disruption of 
these processes, ultimately leading to the 
accumulation of fat typically seen in klf-3 mutants.  
Disruption of klf-3 activity in the klf-3 (ok1975) 
allele contributes to defects in germ cell differentiation 
and oocyte development. Although the KLF-3 protein 
is not present in germ cells or in oocytes, it is con-
stantly and highly expressed during larval develop-
ment, suggesting that its function and regulation in 
larvae is required in later stage-specific cell prolifera-
tion. Reproductive defects could be a result of an in-
crease in fat storage, given that the loss of KLF-3 
function would primarily affect the functioning of the 
intestine. Worm klfs provide a link to the essential 
negative regulatory mechanisms of fat storage in the 
intestine, an organ which has been conserved through 
evolution. The C. elegans intestine presents a useful 
model for use in future studies which strive to ad-
dress the positive and negative impact of neuroendo-
crine signals on lipogenesis and fat deposition [103]. 
Fat storage is a significant energy investment retained 
by the natural selection acting upon metazoan evolu-Int. J. Biol. Sci. 2009, 5 
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tion. Fat storage offsets food shortage, a constant 
threat to animal survival (except humans of recent 
evolution) [104], and is most likely to have first 
emerged in the gut, the most ancient organ. The in-
testine-specificity of worm KLFs and their identifica-
tion as a key factor in fat regulation reinforces the 
assertion that their role in lipid metabolism and en-
ergy homeostasis originated and was adapted early in 
evolutionary history. 
Table 2. List of genes predicted to participate in fatty acid 
transport, and β-oxidation (breakdown) pathways. 
C. elegans Genes 
 
Mammalian name 
 
FA transport  
Dsc-4  Microsomal triglyceride transfer 
protein (MTP)  
vit-2 ( yolk protein70)  Apolipoprotein B (apoB)   
  
vit-3( yolk protein)  Apolipoprotein B (apoB) 
vit-4 ( yolk protein)  Apolipoprotein B (apoB)   
  
vit-5( yolk protein)  Apolipoprotein B (apoB) 
vit-6( yolk protein88 and 
yp115) 
 
Apolipoprotein B (apoB) 
 
Beta oxidation  
Acs-1  Acyl CoA synthase (ACS) 
Acs-2  Acyl CoA synthase (ACS) 
F08A8.1  Acyl CoA oxidase 
F08A8.2  Acyl Co oxidase 
F44C4.5  Palmitoyl protein thioesterase 
T05G5.6  Trifunctional enzyme (ECH) 
Cpt-1  Carnitine palmitoyl transferase 
Cpt-3  Carnitine palmitoyl transferase 
Cpt-6 
 
Carnitine palmitoyl transferase 
 
 
 
Future areas of research will need to examine the 
molecular mechanisms employed by worm KLFs that 
play role (s) in fat metabolism. Exploiting C. elegans 
genetics, biochemistry, and physiology is needed in 
order to determine how the regulatory activities of 
KLFs contribute to normal fat storage and adaptation 
to nutritional stress. Additional studies must be 
aimed at addressing the two key questions that are 
central to understanding the function and regulation 
of KLFs. These two critical questions are: What is the 
molecular basis and regulatory specificities of KLF-3 
in recruiting protein partners and their binding to 
target genes to mediate transcription and how this 
affect fat metabolism? (2) What is the mechanism 
linking the function of KLF-3 to metabolic and sig-
naling pathways and how disruption in KLF function 
leads to fat accumulation? By exploiting unique fea-
tures of C. elegans w e  h o p e  t o  d e v e l o p  a  d e t a i l e d  
mechanistic description of fat accumulation, includ-
ing identification of additional as yet uncharacterized 
components of the C. elegans fat metabolism pathway 
that may suggest new strategies in the treatment of 
obesity. Our lab is currently endeavoring to better 
understand the fundamental methods by which fat 
accumulates following a loss in klf-3 function. Using 
C. elegans homologs of some mammalian fat metabo-
lism genes, we are performing in depth studies that 
how the genes and pathways known to be involved in 
mammalian fat absorption, assembly and transport 
are being affected in response to a loss in the func-
tioning of klfs. 
 
Conclusions  
It is evident from the fact that an inappropriate 
increase and decrease in fat accumulation level is a 
characteristic of many human diseases. Fat storage is 
mediated by a core biochemical pathway that requires 
the activation of transcriptions factors. Considerable 
progress has been made in the identification of the 
transcriptional factors that are involved in the proc-
esses controlling the differentiation of preadipocytes 
into mature fat cells. It is quite clear that we have gone 
many steps forward in the understanding of the KLFs’ 
role in adipocyte differentiation, however, there is still 
a large void in our understanding concerning the 
casc ade of events that result  in  KLFs activation, re-
pression, and interaction with other molecules in ex-
erting their specific functions in fat metabolism. The 
C. elegans has served as a pioneering model for gene 
discovery and functional analysis of many important 
developmental processes. We are using this model 
organism to study fat storage. We believe that study-
ing KLFs in C. elegans will enable us to perform a 
greater range of experiments which are not feasible in 
mammalian models. The identification of C. elegans 
klfs as being key regulators in fat storage through a 
genetically tractable experimental model will allow 
the pursuit of a more comprehensive approach to 
better understanding the biology of fat. It is possible 
that many other unidentified worm genes exist that 
regulate levels of body fat. A thorough genetic analy-
sis of the many mediators of klfs, in concert with an 
examination of their cellular functions in C. elegans, 
will allow a more detailed description of the basic 
regulatory networks conserved between worm and 
humans. As part of the systematic effort to uncover 
treatments for obesity and its associated metabolic 
disorders, it is important to identify components of 
the known and novel signaling pathways that regu-
late fat storage. It will be interesting to determine 
whether worm klfs have similar regulatory functions 
in fat storage as those of mammalian klfs in adipo-Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
634
genesis and other fat metabolic processes. 
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